PharmaEssentia (6446 TW) stock market data APIs
NT$693.2289
-13.78(-2%)
as of March 3, 2026
Try our APIs with
free plan!
PharmaEssentia Financial Data Overview
Price chart is built with
Anychart
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Prev. Close
693.2289
Open
679.447
High
701.6256
Low
662.9993
52 wk Range
395.5448-780
Market Cap
230 589 M
P/E Ratio
53.2819
Shares Outstanding
334 M
Revenue
13 815 M
Dividends (Yield)
0.0014
Beta
0.325
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PharmaEssentia (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEssentia data using free add-ons & libraries
Get PharmaEssentia Fundamental Data
PharmaEssentia Fundamental data includes:
- Net Revenue: 13 815 M
- EBITDA: 4 031 M
- Earnings Per Share: 12
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEssentia News
New
PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
New regimen for ropeginterferon alfa2b-njft enables patients to reach target dose faster, supporting positive clinical outcomes and enabling faster achievement of maintenance dose BURLINGTON, Mass., ...
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
US$46 million investment to establish wholly owned Puerto Rico subsidiary supporting U.S. manufacturing, supply security, and long-term growth of BESREMi® (ropeginterferon alfa-2b) Company plans to ...
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequat...
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Potential expansion of the BESREMi® (ropeginterferon alfa-2b-njft) product label to include adult patients with essential thrombocythemia (ET) BURLINGTON, Mass., January 13, 2026--(BUSINESS WIRE)--P...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
